SCHEMBL4661609

SCHEMBL4661609

CCOC(=O)C(C#N)C(c1ccccc1OC)c1ccccc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
NPSR1 Q6W5P4 3/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
GAA P10253 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
MAPK1 P28482 1/20 0.43
POLB P06746 2/20 0.43
PLIN1 O60240 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
PLIN5 Q00G26 1/20 0.43
ABHD5 Q8WTS1 1/20 0.43
HTT P42858 1/20 0.41
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 2/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4659958 0.90 L3MBTL1 (0.43) SMN1; SMN2L3MBTL1NPSR1NPC1RAB9A
SCHEMBL4659898 0.84 MEN1 (0.44) SMN1; SMN2L3MBTL1NPSR1NPC1RAB9A
SCHEMBL6137068 0.82 SMN1; SMN2 (0.56) SMN1; SMN2L3MBTL1NPSR1NPC1RAB9A
SCHEMBL4659893 0.81 MEN1 (0.42) SMN1; SMN2NPSR1MEN1KMT2ALMNA
SCHEMBL4661479 0.81 ALDH1A1 (0.45) SMN1; SMN2L3MBTL1RAB9AGAAMEN1
SCHEMBL4660013 0.80 NPBWR1 (0.44) SMN1; SMN2GAAMEN1KMT2ALMNA
SCHEMBL490341 0.79 SMN1; SMN2 (0.53) SMN1; SMN2L3MBTL1NPC1GAAMEN1
SCHEMBL4661393 0.78 KMT2A (0.47) L3MBTL1NPC1RAB9AGAAMEN1
SCHEMBL2003346 0.77 MEN1 (0.50) SMN1; SMN2L3MBTL1NPSR1NPC1GAA
SCHEMBL4660164 0.77 SMN1; SMN2 (0.41) SMN1; SMN2L3MBTL1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620102-B1 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS WYETH CORP (US) 2008-12-24 EP disclosed
US-20070299105-A1 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use WYETH (US) 2007-12-27 US disclosed
EP-1620102-A2 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS Wyeth (US) 2006-02-01 EP disclosed
US-20050256132-A1 Use of ER selective NF-kB inhibitors for the treatment of sepsis WYETH (US) 2005-11-17 US disclosed
US-20050004164-A1 2-Cyanopropanoic acid amide and ester derivatives and methods of their use WYETH 2005-01-06 US disclosed
WO-2004099150-A2 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS WYETH (US) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256132-A1 Use of ER selective NF-kB inhibitors for the treatment of sepsis NFKBIA, IKBKB, NFKB2 SMN1; SMN2 3620/4885L3MBTL1 2212/4885NPSR1 1458/4885
US-20070299105-A1 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use HCAR2, PCCA, MCCC2 SMN1; SMN2 1893/4885L3MBTL1 4179/4885NPSR1 2752/4885
US-20050004164-A1 2-Cyanopropanoic acid amide and ester derivatives and methods of their use HCAR2, PCCA, MCCC2 SMN1; SMN2 1969/4885L3MBTL1 4004/4885NPSR1 2530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.